Episodes

  • Screening for Sickle Cell Disease (with Prof David Rees)
    Nov 8 2024

    Join us for an insightful episode featuring Prof David Rees from King’s College Hospital in London as he discusses screening practices for Sickle Cell disease (SCD). Hosted by Dr Sarah de Vlieger, this discussion explores both antenatal and neonatal screening practices for Sickle Cell disease.

    The conversation begins with an examination of antenatal screening challenges, comparing various techniques such as carrier screening, amniocentesis, chorionic villus sampling, and emerging non-invasive prenatal testing. Prof Rees and Dr de Vlieger then address the complex decisions arising from these test results and the disparities in screening access across different countries and cultures.


    Moving to neonatal screening, Prof Rees emphasizes its crucial role in implementing early preventive measures. He advocates for the inclusion of Sickle Cell testing in general neonatal screening programs throughout Europe and aspires for screening to become more accessible in regions with higher disease prevalence.

    Host: Sarah de Vlieger, EHA Head of Education

    Guest: Prof David Rees

    Learn More


    What did you think of this podcast? Share your opinions with us in this short feedback survey.

    Provide Feedback


    Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

    https://ehaedu.org/Campus


    Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

    Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

    Facebook: https://e-h-a.link/facebook

    LinkedIn: https://www.linkedin.com/company/eha/

    Email us: education@ehaweb.org

    Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe

    Show more Show less
    18 mins
  • The Environmental Impact on Hematology Practice (with Dr Stephen Hibbs)
    Nov 1 2024

    Join us for an engaging episode with Dr. Stephen Hibbs from Queen Mary University of London as he discusses the environmental impacts of hematology. Alongside our host Dr. Sarah de Vlieger, they explore how climate change is already affecting hematology, emphasizing that these effects are being felt now rather than in the future.

    The conversation highlights how climate change alters aspects of hematology practice, such as the risk of transfusion-transmitted infections due to evolving disease vectors. Dr. Hibbs describes also the surprising link between extreme heat during pregnancy and an increased risk of children developing ALL (acute lymphoblastic leukemia). He further discusses practice-changing initiatives, like using sevoflurane instead of desflurane as an anesthetic to reduce environmental impact, and explains his work on improving the logistics of blood transfusions to lessen their ecological footprint.

    Finally, Dr. Hibbs encourages hematologists to focus on actionable steps to minimize their environmental impact, advocating for practical changes in clinical practices and increased awareness of the healthcare sector's contribution to global emissions.

    Host: Dr Sarah de Vlieger

    Guest: Dr Stephen Hibbs

    Learn More

    What did you think of this podcast? Share your opinions with us in this short feedback survey.

    Provide Feedback


    Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

    https://ehaedu.org/Campus


    Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

    Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

    Facebook: https://e-h-a.link/facebook

    LinkedIn: https://www.linkedin.com/company/eha/

    Email us: education@ehaweb.org

    Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe

    Show more Show less
    13 mins
  • Synthetic Patients: The Future of Clinical Trials?
    Oct 25 2024

    Join us in this podcast episode, exploring with Prof Matteo Della Porta (Humanitas Research Hospital, Milano, Italy) the emerging role of "synthetic patients" in hematological clinical trials. Innovative generative artificial intelligence models allow today to create synthetic data set based on real patients, suitable to be used as control groups in clinical trials, helping in the identification of disease mechanisms and improving the prognostic risk prediction.

    Prof Della Porta will dig into the challenges and opportunities linked to these new technologies, from the overcoming of privacy barriers to the regulatory needs required with the advent of synthetic data in clinical trial settings, opening the door for novel models in clinical research.

    Host: Dr Enrica Orsini

    Guest: Prof Matteo Della Porta

    Learn More


    What did you think of this podcast? Share your opinions with us in this short feedback survey.

    Provide Feedback


    Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

    https://ehaedu.org/Campus


    Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

    Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

    Facebook: https://e-h-a.link/facebook

    LinkedIn: https://www.linkedin.com/company/eha/

    Email us: education@ehaweb.org

    Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe

    Show more Show less
    15 mins
  • Innovative tools for Disease Monitoring in Multiple Myeloma
    Oct 18 2024

    Join us for an insightful interview with Prof Bruno Paiva from Clinical University of Navarra in Pamplona, Spain, as he and our host Dr. Isabel Olivera-Martinez, discuss the latest technical approaches to improving monitoring, risk stratification and differential diagnosis of patients with monoclonal gammopathies including MGUS (monoclonal gammopathy of unknown significance), smoldering myeloma and multiple myeloma.

    Prof Paiva begins by highlighting the importance of developing less invasive tools to assess MRD, given that multiple myeloma patients are living longer and need to be monitored multiple times.

    He further describes the potential updates to the guidelines of the International Myeloma Working Group that may include the use of mass spectrometry, as a more sensitive method to quantify the M-component as well as the application of next-generation techniques - such as next-generation flow cytometry and next-generation sequencing- to monitor disease in peripheral blood, as a complement to bone marrow assessments.


    Prof Paiva also discusses the two largest ongoing translational studies, which aim to elucidate the “unknown” and define the clinical significance of MGUS and smoldering myeloma for each individual patient.

    Host: Isabel Olivera-Martinez, PhD, Medical Writer 

    Guest: Prof Bruno Paiva


    Learn More


    What did you think of this podcast? Share your opinions with us in this short feedback survey.

    Provide Feedback


    Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

    https://ehaedu.org/Campus


    Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

    Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

    Facebook: https://e-h-a.link/facebook

    LinkedIn: https://www.linkedin.com/company/eha/

    Email us: education@ehaweb.org

    Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe

    Show more Show less
    18 mins
  • Hematology Portraits: Prof Ivo Touw
    Oct 11 2024

    Join us for an interview with Prof Ivo Touw, who has received the prestigious EHA David Grimwade Award for his contributions to the field of hematology research. Prof Touw and his research group focus on molecular signaling in leukemia predisposition syndromes, such as severe congenital neutropenia (SCN). They have described the dysfunction of the membrane receptor for the growth factor G-CSF and its role in SCN and malignant transformation to acute myeloid leukemia. In this interview prof.

    Touw talks about his career path and choices that he has made along the way. He tells about his early fascination with the growth factors and how leukemia cells respond to them, which has driven his scientific career ever since. The simple questions such as “how can the growth factor in some cells only induce a proliferative response and in others both proliferation and differentiation?” or “why does one patient respond to G-SCF therapy and another does not?” triggered the discoveries of the complex underlying biological mechanisms.

    If you want to hear about the stepwise discoveries of the roles of G-SCF mutants, RUNX gene and inflammatory stress and using novel technologies such as induced pluripotent stem (iPS) technology, CRISPR technology and computational biology, tune in to this episode with Prof Ivo Touw. He will also share his thoughts on the new avenues for thinking about therapy for SCN, such as repairing stem cells for autologous transplant or repurposing already available drugs.


    Host: Isabel Olivera-Martinez, PhD, Medical Writer

    Guest: Prof Ivo Touw

    Learn More


    What did you think of this podcast? Share your opinions with us in this short feedback survey.

    Provide Feedback


    Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

    https://ehaedu.org/Campus


    Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

    Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

    Facebook: https://e-h-a.link/facebook

    LinkedIn: https://www.linkedin.com/company/eha/

    Email us: education@ehaweb.org

    Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe

    Show more Show less
    28 mins
  • Preventing Venous Thromboembolism (VTE) in Pregnant Women
    Oct 4 2024

    Join us for an insightful interview with Professor Saskia Middeldorp from Radboud University Medical Center in Nijmegen, The Netherlands, as she and our host Dr. Isabel Olivera-Martinez, discuss the medical and ethical challenges of conducting randomized clinical trials to prevent venous thromboembolism (VTE) during pregnancy.

    VTE is a leading cause of maternal morbidity and mortality, and poses significant risks to pregnant women. Together, explore the relevance of prophylactic treatments like low molecular weight heparin, and the ethical and financial complexities of conducting trials in this population. Learn about the ALIFE2 trial results, that assessed whether LMWH heparin should be used in women with recurrent miscarriage and inherited thrombophilia; well as the latest research and guidelines aimed at improving care for pregnant women at risk of VTE.

    Host: Isabel Olivera-Martinez, PhD, Medical Writer

    Guest: Prof Saskia Middeldorp

    Learn More

    If you liked this podcast and would like to explore related content, you can check out our clinical case about Thrombosis and Hemostasis on the EHA Campus.

    What did you think of this podcast? Share your opinions with us in this short feedback survey.

    Provide Feedback

    Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

    https://ehaedu.org/Campus


    Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

    Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

    Facebook: https://e-h-a.link/facebook

    LinkedIn: https://www.linkedin.com/company/eha/

    Email us: education@ehaweb.org

    Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe

    Show more Show less
    16 mins
  • Gene Therapy for Hemophilia
    Sep 17 2024

    Join us for an insightful interview with Professor Frank Leebeek from Erasmus University in Rotterdam, The Netherlands, as he discusses together with our host, Dr. Isabel Olivera-Martinez, the potential of gene therapy to free hemophilia patients from the standard coagulation factor replacement therapy.

    Prof. Leebeek explains how gene therapy for hemophilia is carried out and differentiates the current possibilities for hemophilia A patients versus those with hemophilia B. He also highlights the advantages and challenges of this life-changing therapy, including its long-term effects, while addressing patient concerns related to safety and accessibility. Finally, he provides a glimpse into the future of gene therapy.

    Host: Isabel Olivera-Martinez, PhD, Medical Writer

    Guest: Prof Frank Leebeek

    Learn More

    If you liked this podcast and would like to explore related content, you can check out our EHA Gene Therapy Techniques Program on the EHA Campus.

    What did you think of this podcast? Share your opinions with us in this short feedback survey.

    Provide Feedback


    Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

    https://ehaedu.org/Campus


    Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

    Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

    Facebook: https://e-h-a.link/facebook

    LinkedIn: https://www.linkedin.com/company/eha/

    Email us: education@ehaweb.org

    Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe

    Show more Show less
    25 mins
  • AI-driven Morphology in Hematology
    Sep 6 2024

    In this podcast episode, we will explore the application of artificial intelligence to morphological diagnosis in hematology. Listening to our host, Dr Mahesh Prahladan (University of Suffolk, UK) you will learn how innovative machine learning and deep learning models have led to the development of AI systems that have been applied in various areas of hematology, including digital pathology.

    As these systems have shown promise in improving diagnostic accuracy and efficiency, they also have a potential for enlarging accessibility to precise diagnostics, through remote digital morphology, and have potential applications in the prognostic stratification of patients.

    According to Dr Prahladan, we are not ready to dispose of our microscopes yet, but automation may become a useful and time-saving tool in the hands of morphologists.

    Host: Dr Enrica Orsini

    Guest: Dr Mahesh Prahladan

    Learn More

    What did you think of this podcast? Share your opinions with us in this short feedback survey.

    Provide Feedback


    Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

    https://ehaedu.org/Campus


    Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

    Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

    Facebook: https://e-h-a.link/facebook

    LinkedIn: https://www.linkedin.com/company/eha/

    Email us: education@ehaweb.org

    Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe

    Show more Show less
    13 mins